Tag: clinical monitoring
-
Heart Failure in AML: New Evidence on Anthracycline Cardiotoxicity
Overview A comprehensive meta-analysis led by researchers from the Netherlands sheds new light on the risk of heart failure in patients with acute myeloid leukemia (AML) who receive anthracycline-based induction therapy. By systematically reviewing 41 studies including 5,995 AML patients, the study consolidates what clinicians have long suspected: anthracyclines, while effective for achieving remission, carry…
-
Heart Failure in AML: New Evidence Emerges
New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…